{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T15:01:53Z","timestamp":1780239713380,"version":"3.54.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rmed.2026.108857","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:35:01Z","timestamp":1777073701000},"page":"108857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Medication adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis on the French cystic fibrosis population from 2012 to 2020"],"prefix":"10.1016","volume":"258","author":[{"given":"Elia","family":"Eid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-5464","authenticated-orcid":false,"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bessou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-5580","authenticated-orcid":false,"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-1970","authenticated-orcid":false,"given":"Marie","family":"Viprey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108857_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108857_bib2","series-title":"Bilan des donn\u00e9es 2023 [French CF Registry. Data Report 2023]","article-title":"Institut national d\u2019\u00e9tudes d\u00e9mographiques (Ined). Registre fran\u00e7ais de la mucoviscidose","year":"2023"},{"key":"10.1016\/j.rmed.2026.108857_bib3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.rmed.2026.108857_bib4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2026.108857_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108857_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108857_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.rmed.2026.108857_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11096-013-9865-x","article-title":"Assessing medication adherence: options to consider","volume":"36","author":"Lehmann","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.rmed.2026.108857_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2011.03.005","article-title":"Longitudinal association between medication adherence and lung health in people with cystic fibrosis","volume":"10","author":"Eakin","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108857_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0060-2024","article-title":"Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review","volume":"33","author":"Hansen","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2026.108857_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1472-6963-12-155","article-title":"Comparison of pharmacy-based measures of medication adherence","volume":"12","author":"Vollmer","year":"2012","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.rmed.2026.108857_bib13","article-title":"Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: a retrospective cohort study using Shizuoka Kokuho database","volume":"101","author":"Saito","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.rmed.2026.108857_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ppul.26774","article-title":"Assessment of long\u2010term medication adherence with cystic fibrosis: an integrated approach","volume":"59","author":"Platt","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.108857_bib16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"Mitchell","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108857_bib22","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","article-title":"A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis","volume":"9","author":"Habib","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2026.108857_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2019.09.018","article-title":"Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France","volume":"19","author":"Olivereau","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108857_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J Drug Assess"},{"key":"10.1016\/j.rmed.2026.108857_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors\u2014an (updated) overview of systematic reviews","volume":"8","author":"Gast","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.rmed.2026.108857_bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1345\/aph.1P607","article-title":"Estimates of Statin discontinuation rates are influenced by exposure and outcome definitions","volume":"45","author":"Geers","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.rmed.2026.108857_bib18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/13696998.2016.1178125","article-title":"Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis","volume":"19","author":"Suthoff","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.rmed.2026.108857_bib19","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/PPA.S211769","article-title":"Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data","volume":"13","author":"Rouz\u00e9","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.rmed.2026.108857_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","article-title":"Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor","volume":"14","author":"Siracusa","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108857_bib21","first-page":"1021","article-title":"Effect of lumacaftor\/ivacaftor on pulmonary exacerbation rates in members with cystic fibrosis in a medicaid population","volume":"25","author":"Tesell","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.rmed.2026.108857_bib24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/antibiotics11111637","article-title":"Longitudinal study of therapeutic adherence in a cystic fibrosis unit: identifying potential factors associated with medication possession ratio","volume":"11","author":"Gir\u00f3n","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.rmed.2026.108857_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00220","article-title":"Multidrug punch cards in primary care: a mixed methods study on patients' preferences and impact on adherence","volume":"5","author":"Boeni","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2026.108857_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1378\/chest.13-1926","article-title":"Pulmonary medication adherence and health-care use in cystic fibrosis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T14:36:56Z","timestamp":1780238216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0954611126002258"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108857","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis on the French cystic fibrosis population from 2012 to 2020","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108857"}}